Latest Articles
Kissei Pharmaceutical Aktie surges on Icelty launch for uterine fibroids in Japan - AD HOC NEWS
Kissei Pharmaceutical Aktie surges on Icelty launch for uterine fibroids in Japan AD HOC NEWS
Published: March 20, 2026, 5:40 a.m.
Louisiana lawmaker creates uterine fibroid commission to address women’s health gaps - KSLA
Louisiana lawmaker creates uterine fibroid commission to address women’s health gaps KSLA
Published: March 7, 2026, 12:42 a.m.
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment - The Malaysian Reserve
Apotex Strengthens Commitment to Women's Health with Exclusive Canadian Rights to "Linzagolix" for Uterine Fibroid Treatment The Malaysian Reserve
Published: Oct. 8, 2025, 10:56 a.m.
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 - BMC Public Health
The global burden of polycystic ovary syndrome, endometriosis, uterine fibroids, cervical cancer, uterine cancer, and ovarian cancer from 1990 to 2021 BMC Public Health
Published: May 14, 2025, 5:32 a.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - BioSpace
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids BioSpace
Published: May 7, 2025, 1:28 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - The Manila Times
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids The Manila Times
Published: May 7, 2025, 12:24 p.m.
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - PR Newswire
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids PR Newswire
Published: May 7, 2025, noon
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids - 스페셜타임스
TiumBio and Daewon Pharmaceutical Successfully Complete Phase 2 Clinical Trial of 'Merigolix (TU2670/DW4902)' for Uterine Fibroids 스페셜타임스
Published: May 7, 2025, noon
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial - koreabiomed.com
Daewon Pharm’s uterine fibroid drug meets primary endpoint in P2 trial koreabiomed.com
Published: May 7, 2025, 6:51 a.m.
Uterine fibroids are a common medical condition, and for some women it can be devastating - MSN
Uterine fibroids are a common medical condition, and for some women it can be devastating MSN
Published: April 5, 2025, 7:13 p.m.
Link copied to clipboard!